News | June 10, 2022
Olema Oncology and Aurigene collaboration to discover and develop novel cancer therapies
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
The Accelerator will develop products and solutions that will support Sanofi’s mission to transform the practice of medicine with the use of digital, data and artificial intelligence (AI).
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Healthcare is timely and personal – and its delivery should be too
Based on a post hoc analysis, fewer required respiratory interventions
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
CerTest Biotec uses the BD MAX molecular diagnostic system open system reagent suite to develop RT-PCR detection kit
Cloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
Subscribe To Our Newsletter & Stay Updated
